The annual "soul bargaining" between experts from the medical insurance bureau and representatives of pharmaceutical enterprises came to an end. COVID-19 oral medicine, high-value new tumor medicine, rare disease medicine and other new "talks" for the first time became the focus of this medical insurance negotiation. So, what is the outcome of the negotiation? On the 18th, the National Medical Insurance Administration held a press conference to introduce the relevant situation of the adjustment of the national medical insurance drug catalogue in 2022. How much money can patients save? ——It is estimated that the burden of patients will be reduced by more than 90 billion yuan in the next two years. According to Huang Xinyu, deputy director of the Medical Service Management Department of the National Health Insurance Bureau, the adjustment of the national basic medical insurance, industrial injury insurance and maternity insurance drug catalogue in 2022 has been successfully completed. In this adjustment, a total of 111 drugs were added to the list. The newly added drugs include 56 drugs for chronic diseases such as hypertension, diabetes, hyperlipidemia and psychosis, 23 drugs for tumors, 17 drugs for anti infection, 7 drugs for rare diseases, 2 drugs for treatment of COVID-19, and 6 drugs for other fields. After this round of adjustment, the total number of drugs in the national medical insurance drug catalog reached 2967, including 1586 western drugs and 1381 proprietary Chinese drugs; There are still 892 kinds of traditional Chinese medicine pieces without adjustment. From the perspective of negotiation and bidding, 147 drugs outside the catalog participated in the negotiation and bidding (including the renewal negotiation of drugs in the original catalog), and 121 drugs were successfully negotiated or bidding, with an overall success rate of 82.3%. The average price drop of newly admitted drugs through negotiation and bidding reached 60.1%, basically the same as last year. From the perspective of patients' burden, the adjustment is expected to reduce the burden of patients by more than 90 billion yuan in the next two years through the double negative effects of negotiated price reduction and medical insurance reimbursement. Huang Xinyu said that in the past five years, the National Health Insurance Bureau has adhered to the functional orientation of "basic insurance", resolutely put an end to the entry of sky-priced drugs into medical insurance, and, relying on the huge market size of China, significantly reduced the price of drugs in the new access catalogue through negotiation. In many treatment fields, China's drug price has changed from the original highland to the global depression, and China's drug price has become the reference of drug pricing in developed countries for the first time. "From 2018 to 2022, imported drugs basically gave the lowest price in the world. In 2022, the method of competitive access was innovatively put forward, which solved the problem of high prices of some non-exclusive drugs and difficulty in entering the list, and guided enterprises to actively reduce prices in the form of competitive prices in exchange for the opportunity to enter the medical insurance list." He said. How about the negotiation results of COVID-19? ——Before Azovudine tablets and other two drugs were officially included in the national medical insurance directory, the head of the National Medical Insurance Bureau disclosed that this year, a total of three COVID-19 therapeutic drugs, Azovudine tablets, Nematvir tablets/Litonavir tablets combination packaging (Paxlovid for short), and Qingfei Paidu Granules, participated in the negotiations through the procedures of independent declaration, form review, expert review, etc. So what is the result of the negotiation? According to Huang Xinyu, this medical insurance negotiation fully supports the treatment of COVID-19 infection. For the third year in a row, COVID-19 took therapeutic drugs as the access condition of the medical insurance catalogue, and two drugs, including Azovudine Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance catalogue through price reduction through negotiation. The Tenth Edition COVID-19